Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization

Topiramate is an antiseizure medication used to treat epilepsy and migraine and is commonly prescribed for appetite suppression and weight loss. However, whether its pharmacological actions influence eating disorder risk remains unclear. We applied drug-target Mendelian randomization (MR) to investigate potential causal effects of topiramate on the risk of anorexia nervosa (AN; 24,223 cases and 1,243,971 controls) and binge-eating behaviour (BE; 39,279 cases and 1,227,436 controls) and, exploratorily, eight other psychiatric disorders: attention-deficit/hyperactivity disorder, anxiety disorder

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.